Soranib 200 mg Tablets – 1 pack / 120 tabs, 1 pack / 30 tabs

At a Glance

Generic Name: Sorafenib

Brand Name: Soranib

Strength & Pack Options: 200 mg tablets; 1 pack / 120 tabs and 1 pack / 30 tabs

Dosage Form: Film-coated oral tablets

Therapeutic Class: Multikinase inhibitor, targeted anticancer therapy

Main Indications: Advanced hepatocellular carcinoma, advanced renal cell carcinoma and differentiated thyroid carcinoma as indicated

Use in Therapy: Systemic oral treatment for unresectable or metastatic disease as per specialist guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry, protected place away from moisture and light

Product Description

Soranib 200 mg contains sorafenib, a targeted multikinase inhibitor used in the systemic treatment of certain advanced solid tumours.
Many liver, kidney and thyroid cancers rely on signalling pathways that control cell growth and blood vessel formation.
By blocking specific kinases within these pathways, Soranib sorafenib tablets help slow tumour progression in patients with unresectable or metastatic disease.

The Soranib 200 mg tablet is widely recognised as a generic sorafenib 200 mg option.
At Generic Meds Mart, Soranib is offered as a variable product with two convenient pack sizes:
1 pack / 120 tablets and 1 pack / 30 tablets. This flexibility allows your oncologist and pharmacist to match the pack size with treatment duration,
follow-up intervals and budget in USD.

In practice, sorafenib is used for unresectable or metastatic hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC)
and certain forms of differentiated thyroid carcinoma that are refractory to radioactive iodine.
Soranib 200 mg sorafenib tablets provide the same active ingredient and strength as originator sorafenib while offering an accessible generic alternative for long courses of therapy.

The 120-tablet pack is often suitable for roughly one and a half to two months of treatment, depending on the prescribed daily dose, whereas the
30-tablet pack can be used for shorter cycles, treatment initiation, dose adjustments or smaller, more frequent purchases.
Regardless of pack size, Soranib 200 mg must always be used exactly as directed by an experienced oncologist.
Generic Meds Mart does not initiate or modify cancer treatment; our role is to provide reliable access to generic sorafenib tablets that match your written treatment plan.

Key Uses

Soranib 200 mg (sorafenib) tablets are generally used for the following indications under specialist supervision:

• Unresectable or metastatic hepatocellular carcinoma (advanced liver cancer)
• Advanced renal cell carcinoma (kidney cancer) according to current guidelines
• Progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine

Your oncology team will decide whether Soranib 200 mg is appropriate and how it fits within your overall systemic therapy plan.

How Sorafenib Works in Chemotherapy

Sorafenib is an oral targeted anticancer agent and a multikinase inhibitor.
It is frequently grouped with modern systemic chemotherapy and targeted therapies for liver, kidney and thyroid cancer, although its mechanism differs from classic cytotoxic drugs.

Soranib sorafenib tablets inhibit several intracellular and cell-surface kinases, including RAF kinases and receptors in the
VEGFR and PDGFR pathways. These kinases promote tumour cell proliferation and tumour angiogenesis (new blood vessel formation).
By blocking these targets, Soranib 200 mg exerts both antiproliferative and anti-angiogenic effects, which can slow tumour growth and reduce blood supply to the tumour.

This dual mechanism may help stabilise disease and prolong progression-free survival in selected patients with advanced HCC, RCC or thyroid cancer.
Because these pathways are also present in normal tissues, sorafenib therapy can cause systemic side effects, making careful monitoring by an experienced oncologist essential.

Dosage & Administration

Soranib 200 mg sorafenib tablets must always be taken exactly as prescribed by your oncology team.
The total daily dose, treatment schedule and any dose modifications are based on your diagnosis, body weight, organ function, other medicines and side-effect profile.

• A commonly used starting dose is 400 mg twice daily (two 200 mg Soranib tablets in the morning and two in the evening), unless your doctor advises otherwise.
• Take tablets by mouth with water, with or without food, following your doctor’s specific instructions about meals.
• Swallow Soranib tablets whole; do not crush, split or chew them unless a pharmacist gives specific handling advice.
• Take doses at approximately the same times each day to maintain consistent sorafenib exposure.
• If you miss a dose, follow the written guidance from your treatment centre; do not double your next dose unless your doctor specifically instructs you to.

Your oncologist may adjust or temporarily interrupt Soranib 200 mg therapy if you experience significant side effects or abnormal laboratory results.

Precautions

Before starting Soranib 200 mg, tell your healthcare team about your full medical history and all medicines, supplements and herbal products you use. Key precautions include:

• Pre-existing liver disease, cirrhosis, viral hepatitis or abnormal liver function tests
• History of cardiovascular disease, coronary artery disease, arrhythmias, heart failure or uncontrolled hypertension
• Recent major surgery or planned operations, due to possible effects on wound healing
• History of bleeding disorders, gastrointestinal ulcers, varices or previous significant haemorrhage
• Use of anticoagulants or antiplatelet medicines that may increase bleeding risk
• Concomitant use of strong inducers or inhibitors of drug-metabolising enzymes that may alter sorafenib levels
• Pregnancy or breastfeeding; sorafenib tablets are not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use reliable contraception during and for a period after Soranib sorafenib treatment, as directed by their oncologist.

Sorafenib Side Effects

Common side effects

Many patients experience side effects when they first start Soranib 200 mg. Common adverse reactions may include:

• Hand–foot skin reaction (redness, pain, thickening or blistering on palms and soles)
• Skin rash, dryness or peeling
• Diarrhea or loose stools
• Fatigue, low energy or asthenia
• Nausea, occasional vomiting or reduced appetite
• Weight loss over time
• Hair thinning or alopecia
• Mild to moderate increases in blood pressure

These effects are often manageable with supportive measures, topical treatments, dose reductions or temporary interruptions as decided by your oncology team.

Serious side effects

Less common but serious side effects of sorafenib require urgent medical attention. These may include:

• Severe hypertension or hypertensive crisis
• Chest pain, shortness of breath or signs of heart ischaemia
• Significant bleeding, such as black or bloody stools, coughing or vomiting blood
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, intense upper abdominal pain
• Gastrointestinal perforation or severe, persistent abdominal pain
• Severe skin reactions, blistering or mucosal involvement
• Sudden severe headache, visual changes or neurological symptoms suggestive of a vascular event

If you experience any of these serious symptoms while taking Soranib 200 mg sorafenib tablets, seek emergency medical care immediately and contact your oncology team without delay.

Storage

• Store Soranib 200 mg tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton to protect them from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use after the expiry date printed on the packaging.

Ask your pharmacist how to safely dispose of unused or expired Soranib sorafenib tablets; do not throw them into household waste or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to providing safe access to key oncology medicines such as
Soranib 200 mg sorafenib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a reliable export record.

When you buy Soranib 200 mg online from Generic Meds Mart, you benefit from:

• Flexible pack sizes (30 and 120 tablets) that reflect real clinical usage
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured product information to support discussions with your oncology team
• Customer support to help with ordering, payment and delivery questions

Order Now

Soranib 200 mg sorafenib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Soranib online, ensure your oncologist has confirmed sorafenib as part of your treatment plan and specified the daily dose and intended duration.

Select the appropriate pack size – Soranib 200 mg 1 pack / 120 tabs or 1 pack / 30 tabs – add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. Treatment decisions and dose adjustments must always remain with your healthcare team.

Sorafenat 200 mg Tablets – 1 pack / 30, 60, 120 tabs

At a Glance

Generic Name: Sorafenib

Brand Name: Sorafenat

Strength & Pack Options: 200 mg film-coated tablets; 1 pack / 30, 60 and 120 tabs

Dosage Form: Oral film-coated tablets

Therapeutic Class: Multikinase inhibitor, targeted anticancer therapy

Main Indications: Advanced hepatocellular carcinoma, advanced renal cell carcinoma and differentiated thyroid carcinoma as indicated

Use in Therapy: Systemic oral treatment for unresectable or metastatic disease as per specialist guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry, protected place away from moisture and light

Product Description

Sorafenat 200 mg contains sorafenib, a targeted multikinase inhibitor used in the systemic treatment of certain advanced solid tumours.
Many liver, kidney and thyroid cancers depend on kinase signalling and tumour blood vessel formation to grow and spread.
By blocking specific kinases within these pathways, Sorafenat sorafenib tablets help slow tumour progression in patients with unresectable or metastatic disease.

As a generic sorafenib 200 mg product, Sorafenat 200 mg provides the same active ingredient and strength as the originator brand while often being more accessible in USD.
At Generic Meds Mart, Sorafenat is available as a variable product with three pack sizes: 1 pack / 30 tablets, 1 pack / 60 tablets and 1 pack / 120 tablets.
This flexibility allows your oncology team to match the quantity of Sorafenat sorafenib tablets to your treatment cycle, review interval and budget.

In clinical practice, sorafenib is used for unresectable or metastatic hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC)
and certain forms of differentiated thyroid carcinoma that no longer respond adequately to radioactive iodine.
Sorafenat 200 mg sorafenib tablets offer a generic option in these settings when prescribed by an experienced oncologist.

The 30-tablet pack is often chosen for treatment initiation, dose adjustments or shorter monitored cycles.
The 60-tablet pack covers several weeks of therapy at common doses, and the 120-tablet pack is convenient when your dose is stable and you prefer fewer repeat orders.
Regardless of pack size, Sorafenat 200 mg must always be taken exactly as described in your written treatment plan.
Generic Meds Mart does not initiate or modify therapy; our role is to provide reliable access to generic sorafenib tablets and clear, structured information.

Key Uses

Sorafenat 200 mg (sorafenib) tablets are generally used for the following indications under specialist supervision:

• Unresectable or metastatic hepatocellular carcinoma (advanced liver cancer)
• Advanced renal cell carcinoma (kidney cancer) when systemic multikinase inhibitor therapy is indicated
• Progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine

Your oncology team will determine whether Sorafenat 200 mg is appropriate for you and how it fits into your overall systemic treatment strategy.

How Sorafenib Works in Chemotherapy

Sorafenib is an oral targeted anticancer medicine from the class of multikinase inhibitors.
It is often grouped with modern systemic chemotherapy and targeted therapies for liver, kidney and thyroid cancer, though its mechanism differs from classic cytotoxic drugs.

Sorafenat sorafenib tablets inhibit several intracellular and cell-surface kinases, including RAF kinases and receptors in the
VEGFR and PDGFR pathways. These kinases promote tumour cell proliferation and tumour angiogenesis (formation of new blood vessels).
By blocking these targets, Sorafenat 200 mg exerts both antiproliferative and anti-angiogenic effects, helping to slow tumour growth and reduce tumour blood supply.

This dual action may help stabilise disease and prolong progression-free survival in selected patients with advanced HCC, RCC or differentiated thyroid carcinoma.
Because these pathways are also present in normal tissues, sorafenib therapy can cause systemic side effects, so close monitoring by an experienced oncologist is essential.

Dosage & Administration

Sorafenat 200 mg sorafenib tablets must always be taken exactly as prescribed by your oncology team.
The total daily dose, treatment schedule and any changes or interruptions are defined by your doctor based on your diagnosis, organ function, concomitant medicines and tolerance.

• A frequently used starting dose is 800 mg of sorafenib per day (two 200 mg Sorafenat tablets twice daily), unless your doctor advises otherwise.
• Take Sorafenat tablets by mouth with water, following your doctor’s instructions on whether to take them with or without food.
• Swallow tablets whole; do not break, crush or chew Sorafenat 200 mg unless your pharmacist provides specific handling instructions.
• Take doses at approximately the same times each day to maintain consistent sorafenib exposure.
• If you miss a dose, follow the written instructions from your treatment centre; do not double your next dose unless your doctor specifically instructs you to do so.

Your oncologist may reduce the dose or temporarily interrupt Sorafenat 200 mg therapy if significant side effects or abnormal test results occur.

Precautions

Before starting Sorafenat 200 mg, tell your healthcare team about your full medical history and all medicines, supplements and herbal products you are taking. Key precautions include:

• Pre-existing liver disease, cirrhosis, viral hepatitis or abnormal liver function tests
• History of cardiovascular disease, coronary artery disease, arrhythmias, heart failure or uncontrolled hypertension
• Recent major surgery or planned operations, due to potential effects on wound healing
• History of bleeding disorders, gastrointestinal ulcers, varices or significant prior haemorrhage
• Use of anticoagulants or antiplatelet medicines that may increase bleeding risk
• Use of strong inducers or inhibitors of drug-metabolising enzymes that may alter sorafenib levels
• Pregnancy or breastfeeding; sorafenib tablets are not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use effective contraception during and for a period after Sorafenat sorafenib treatment, as directed by their oncologist.

Sorafenib Side Effects

Common side effects

Many patients experience side effects when starting Sorafenat 200 mg. Common adverse reactions include:

• Hand–foot skin reaction (redness, pain, thickening or blistering on palms and soles)
• Skin rash, dryness, itching or peeling
• Diarrhea or loose stools
• Fatigue, low energy or asthenia
• Nausea, occasional vomiting or reduced appetite
• Weight loss over time
• Hair thinning or alopecia
• Mild to moderate increases in blood pressure

These side effects are often manageable with supportive care, topical treatments, dose adjustments or temporary interruptions, as decided by your oncology team.

Serious side effects

Less common but serious side effects of sorafenib require urgent medical attention. These may include:

• Severe or uncontrolled hypertension or hypertensive crisis
• Chest pain, shortness of breath or signs of cardiac ischaemia
• Significant bleeding, such as black or bloody stools, vomiting blood or coughing up blood
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, intense upper abdominal pain
• Gastrointestinal perforation or severe, persistent abdominal pain
• Severe skin reactions, blistering or mucosal involvement
• Sudden severe headache, visual changes or neurological symptoms suggestive of a vascular event

If you experience any of these serious symptoms while taking Sorafenat 200 mg sorafenib tablets, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Sorafenat 200 mg tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton to protect them from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use the product after the expiry date printed on the packaging.

Ask your pharmacist how to safely dispose of unused or expired Sorafenat sorafenib tablets; do not throw them into household waste or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to providing safe access to key oncology medicines such as
Sorafenat 200 mg sorafenib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a reliable export record.

When you buy Sorafenat 200 mg online from Generic Meds Mart, you benefit from:

• Flexible pack sizes (30, 60 and 120 tablets) that reflect real clinical usage
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured product information to support discussions with your oncology team
• Customer support to help with ordering, payment and delivery questions

Order Now

Sorafenat 200 mg sorafenib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Sorafenat online, ensure your oncologist has confirmed sorafenib as part of your treatment plan and specified the daily dose and intended duration.

Select the appropriate pack size – Sorafenat 200 mg 1 pack / 30 tabs, 1 pack / 60 tabs or 1 pack / 120 tabs – add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.

Lenshil 4 mg and 10 mg Lenvatinib Capsules (1 pack / 10 caps)

At a Glance

Generic Name: Lenvatinib

Brand Name: Lenshil

Strength & Pack Size: 4 mg and 10 mg capsules; 1 pack / 10 capsules each

Dosage Form & Route: Oral capsules taken once daily by mouth

Therapeutic Class: Oral receptor tyrosine kinase inhibitor (targeted anticancer therapy)

Primary Indications: Differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and selected endometrial cancers

Usual Daily Dose: Combination of 4 mg and 10 mg capsules to reach the total daily lenvatinib dose defined by protocol and body weight

Prescription Status: Prescription-only oncology medicine for specialist use

Storage: Store below 25–30 °C, protect from moisture and light, keep out of reach of children

Product Description

Lenshil is a branded lenvatinib capsule used as an oral targeted therapy in several advanced or progressive cancers. Each capsule contains lenvatinib, a receptor tyrosine kinase inhibitor that interferes with signalling pathways driving tumour growth and the formation of new blood vessels feeding tumours. Lenshil 4 mg and Lenshil 10 mg capsules are designed to be combined in different ways to match the total daily lenvatinib dose specified in oncology protocols, taking into account body weight, indication and tolerability.

Lenvatinib is most widely recognised for its role in progressive or advanced differentiated thyroid cancer that is refractory to radioactive iodine treatment. It is also used in unresectable hepatocellular carcinoma (liver cancer), in selected renal cell carcinoma regimens and, in combination with immunotherapy, in certain advanced endometrial cancers when other options are not suitable or have failed. Lenshil lenvatinib capsules provide a convenient oral formulation that can be taken at home once daily, while all dosing decisions, monitoring and adjustments remain under the supervision of an oncology specialist.

Generic Meds Mart supplies Lenshil lenvatinib 4 mg and 10 mg capsules in original manufacturer packaging sourced from licensed distributors. Each pack of 10 capsules carries clear labelling of the strength, generic name, batch number, expiry date and storage conditions so that clinics and pharmacies can verify the medicine against the prescribed regimen. Orders are shipped in plain outer packaging that does not reveal the nature of the treatment, helping to protect patient privacy while supporting continuity of care in regions where accessing lenvatinib locally may be challenging.

Key Uses

Lenshil 4 mg and 10 mg capsules are used in adults for the treatment of several cancers where lenvatinib has a recognised role in international or local guidelines. These include progressive, locally recurrent or metastatic differentiated thyroid cancer that no longer responds adequately to radioactive iodine therapy, unresectable hepatocellular carcinoma in certain treatment settings, advanced renal cell carcinoma when given with other agents and selected advanced endometrial cancers in combination with immunotherapy.

The decision to start lenvatinib and to use Lenshil specifically depends on tumour type, staging, prior treatments, overall health, comorbidities and laboratory results. Lenvatinib is a powerful targeted therapy and is not appropriate for every patient with these cancers. Your oncology team will review imaging, histology, biomarker status and other systemic options before confirming that a lenvatinib-based regimen is suitable. Lenshil capsules should never be started, stopped or substituted without direct instruction from your treating oncologist.

How Lenvatinib Works in Chemotherapy

Lenvatinib, the active ingredient in Lenshil capsules, is a multi-targeted receptor tyrosine kinase inhibitor. It blocks the activity of several vascular endothelial growth factor (VEGF) receptors and other tyrosine kinases involved in tumour angiogenesis and cell proliferation. By inhibiting these receptors, lenvatinib disrupts the signalling pathways that drive new blood vessel formation and support tumour growth and survival.

This dual effect – restricting the tumour’s blood supply and interfering with signals that promote cancer cell division – can lead to shrinking of tumours or stabilisation of disease in responsive patients. In differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial cancer, lenvatinib is often part of a broader treatment strategy that may include prior surgery, radioactive iodine, other systemic therapies and, in some cases, combination immunotherapy. Although it is sometimes described as “chemotherapy”, lenvatinib is technically a targeted agent rather than a traditional cytotoxic drug, but it is still associated with significant side effects that require careful monitoring and dose adjustment.

Dosage & Administration

Lenshil lenvatinib capsules are taken once daily by mouth, with or without food, at approximately the same time each day. The total daily lenvatinib dose is calculated by the treating oncologist according to the type of cancer, body weight, liver function, kidney function, combination partners and local prescribing information. Different combinations of Lenshil 4 mg and Lenshil 10 mg capsules are used to reach that total daily dose; for example, a regimen might use a 10 mg capsule plus one or more 4 mg capsules each day, or several 4 mg capsules in patients requiring lower doses.

Capsules should be swallowed whole with water and should not be crushed, chewed or opened unless a specialist gives explicit alternative instructions. If a dose is missed, your oncology team will advise whether to take it later the same day or to skip it and continue with the next scheduled dose, but doses should never be doubled to “catch up”. Throughout treatment, blood pressure, kidney function, liver function, protein in the urine and other parameters are checked regularly, and the lenvatinib dose may be interrupted, reduced or, in some cases, stopped altogether in response to side effects or disease progression.

Precautions

Before starting Lenshil, your oncology team will review your medical history carefully, including any cardiovascular disease, history of blood clots or strokes, uncontrolled hypertension, bleeding disorders, liver or kidney impairment, thyroid function, electrolyte abnormalities and prior treatments. Lenvatinib can increase blood pressure, affect heart and blood vessel health, impact kidney function and cause proteinuria, so blood pressure and laboratory tests need to be monitored closely. Pre-existing uncontrolled hypertension should be treated before lenvatinib is started, and antihypertensive therapy may be adjusted while you are on Lenshil.

Lenvatinib can interfere with wound healing and may increase the risk of bleeding or fistula formation in certain locations, so planned surgery or recent major operations should be discussed in detail with your oncology and surgical teams. Because lenvatinib can harm a developing baby, effective contraception is recommended for both women and men of reproductive potential during treatment and for a period after the last dose, as defined in local guidance. Breastfeeding is generally not recommended during lenvatinib therapy. You should inform your doctor about all prescription medicines, over-the-counter drugs and herbal supplements you are taking, as some may interact with lenvatinib or its side effects.

Lenvatinib Side Effects

Common side effects

Common side effects of lenvatinib include high blood pressure, diarrhoea, decreased appetite, weight loss, nausea, vomiting, fatigue, weakness, abdominal pain, mouth sores, headache, hoarse voice and changes in taste. Swelling of the legs, protein in the urine and mild changes in kidney or liver blood tests are also frequently reported. Many patients experience some combination of these effects, especially in the first weeks and months of treatment, and dose adjustments or supportive medicines are often used to help manage them.

In many cases, common side effects can be reduced by careful blood pressure control, dietary adjustments, anti-diarrhoeal or anti-nausea medicines, mouth care for oral soreness and regular monitoring. Your oncology team will give you detailed instructions on what to report immediately and what can be discussed at the next scheduled visit. It is important not to ignore persistent symptoms, even if they seem manageable, because early dose modifications can prevent more serious complications.

Serious side effects

Serious side effects of lenvatinib are less common but require urgent medical attention and sometimes permanent discontinuation of therapy. These include very high blood pressure or hypertensive crisis, symptoms of stroke such as sudden weakness on one side of the body, confusion, difficulty speaking, vision changes or severe headache, signs of heart problems such as chest pain, shortness of breath or irregular heartbeat, severe bleeding, coughing up blood or black, tarry stools and severe abdominal pain that could signal bowel perforation or fistula formation.

Other serious risks include significant kidney injury with sharply reduced urine output, marked proteinuria, severe liver dysfunction with jaundice and coagulopathy and rare but serious brain or neurological events. If you experience any sudden or severe symptom – especially chest pain, difficulty breathing, neurological changes, severe headache, major bleeding or profound weakness – you should seek emergency medical care immediately and contact your oncology team as soon as possible. Do not take extra doses or stop Lenshil abruptly without professional guidance, but do treat these warning signs as urgent.

Storage

Lenshil 4 mg and 10 mg lenvatinib capsules should be stored at room temperature, generally below 25–30 degrees Celsius, in a dry place away from heat and direct sunlight. Keep the capsules in their original blister strip and outer carton until it is time to take a dose, to protect them from moisture and to avoid mix-ups with other medicines. Do not store Lenshil in the bathroom or near sinks where humidity is high. As with all potent anticancer medicines, the pack should be kept out of sight and reach of children and pets. Do not use the capsules after the expiry date printed on the packaging, and follow local guidance or your clinic’s advice on how to dispose of unused or expired medicines safely.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on reliable access to targeted oncology medicines such as Lenshil lenvatinib capsules for patients and clinics in markets where supply or pricing can be difficult. We work only with licensed manufacturers and authorised distributors that follow Good Manufacturing Practice standards and maintain traceable batch and expiry records. Lenshil 4 mg and Lenshil 10 mg are provided in original, sealed cartons so that oncology pharmacists and treating clinicians can verify the brand, strength and batch details against their protocols before dispensing.

Orders are processed in USD through secure checkout, and shipments are prepared in neutral external packaging with no visible references to cancer, lenvatinib, thyroid disease or other diagnoses. Where available, tracked delivery options help align medication arrival with scheduled oncology visits and imaging, reducing the chance of unplanned breaks in therapy due to supply issues. While Generic Meds Mart supports access and logistics, all choices regarding whether lenvatinib is appropriate, what daily dose should be used and how long treatment should continue rest solely with qualified oncology professionals.

Order Now

Before ordering Lenshil 4 mg or 10 mg capsules from Generic Meds Mart, you should have a clearly documented treatment plan from your oncology team that specifically includes lenvatinib, along with the target daily dose, expected duration and monitoring schedule. Your specialists will base this plan on tumour type, prior treatments, imaging, laboratory results and your overall health status. Once the regimen is confirmed, you or your clinic can calculate how many Lenshil packs are required for each treatment period and select the appropriate combination of 4 mg and 10 mg strengths.

You should not attempt to self-prescribe lenvatinib, change your Lenshil dose on your own or substitute one strength for another without direct instruction from your oncologist. If you experience new or worsening symptoms while taking Lenshil, including severe hypertension, neurological changes, bleeding, chest pain, breathing difficulties or marked swelling, contact your treating team immediately rather than simply stopping the capsules. Generic Meds Mart’s role is to help ensure that the prescribed Lenshil strengths are available in a timely, discreet and verifiable way; the complex clinical management of your cancer always remains in the hands of your oncology team.

FAQ about Lenshil (Lenvatinib)

Q1: What cancers is Lenshil used to treat?

Lenshil contains lenvatinib, a tyrosine kinase inhibitor used in progressive or advanced differentiated thyroid cancer that no longer responds to radioactive iodine, as well as in selected cases of unresectable hepatocellular carcinoma, advanced renal cell carcinoma and certain advanced endometrial cancers. The exact indication and regimen are defined by your oncology team based on current guidelines and your clinical situation.

Q2: How should I take Lenshil capsules each day?

Lenshil is usually taken once daily at about the same time each day, with or without food. Your oncologist will prescribe a total daily lenvatinib dose and indicate how many 4 mg and 10 mg capsules you should take to reach that dose. Swallow the capsules whole with water and do not crush, chew or open them unless your specialist gives specific alternative instructions.

Q3: What happens if I miss a dose of Lenshil?

If you miss a dose of Lenshil and remember relatively soon, your oncology team may advise you to take it the same day and then return to your usual schedule. If it is close to the time of your next dose, they may recommend skipping the missed dose. You should not double doses to make up for a missed one. For personalised advice, follow the instructions given by your clinic and discuss any adherence issues at your next visit.

Q4: Can I drink alcohol while taking Lenshil?

Light or occasional alcohol may be permitted for some patients, but both alcohol and lenvatinib can affect blood pressure, liver function and overall tolerance of therapy. Because of this, you should discuss alcohol use directly with your oncologist, who can advise whether it is safe for you and, if so, in what amounts. Avoid drinking alcohol if you already have significant liver problems or if your doctor has advised against it.

Q5: How long will I need to stay on Lenshil treatment?

Treatment duration with Lenshil varies from person to person. Some patients continue lenvatinib therapy as long as the disease remains controlled and side effects are manageable, while others may stop or switch therapies due to intolerance or progression. Your oncology team will monitor your response with scans, blood tests and clinical assessments and will decide whether to continue, adjust or discontinue lenvatinib based on these results and your overall health.

Regonat Regorafenib – 40 mg (1 pack / 28 tablets)

At a Glance

Generic Name: Regorafenib

Brand Name: Regonat

Strength & Pack Size: Regonat 40 mg – 1 pack / 28 tablets

Dosage Form: Oral film-coated tablets

Therapeutic Class: Multikinase inhibitor, targeted anticancer therapy

Main Indications: Metastatic colorectal cancer, unresectable gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma as indicated

Use in Therapy: Systemic oral treatment for unresectable or metastatic disease after prior lines of therapy

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from light and moisture

Product Description

Regonat 40 mg contains regorafenib, an oral multikinase inhibitor used as targeted therapy in selected patients with advanced solid tumours.
It is commonly prescribed for metastatic colorectal cancer, unresectable gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma after
standard options have failed or are no longer effective. Regonat regorafenib 40 mg tablets act on multiple signalling pathways involved in tumour growth and tumour angiogenesis,
helping to slow disease progression under specialist supervision.

Each Regonat 40 mg tablet contains 40 mg of regorafenib, and the 1 pack / 28 tablets presentation aligns with typical 28-day treatment cycles
(three weeks on therapy followed by one week off) used in many protocols. As a generic regorafenib 40 mg product, Regonat offers the same active ingredient and strength
as originator regorafenib while providing a more accessible price in USD for patients requiring repeated cycles of targeted therapy.

When you buy Regonat 40 mg online from Generic Meds Mart, you receive regorafenib 40 mg tablets in original manufacturer packaging with clear labelling, batch number and expiry date.
We source Regonat only from licensed manufacturers and authorised distributors that follow recognised GMP standards. Our role is limited to safe, structured supply; all treatment decisions remain with your oncology team.

Key Uses

Regonat 40 mg regorafenib tablets are generally used under specialist supervision for:

• Metastatic colorectal cancer in adults previously treated with standard chemotherapy and targeted agents
• Unresectable or metastatic gastrointestinal stromal tumours (GIST) after failure or intolerance of other tyrosine kinase inhibitors
• Hepatocellular carcinoma in patients who have received prior systemic therapy when regorafenib is recommended

Your oncologist will determine whether Regonat 40 mg is appropriate based on tumour type, prior treatments, liver function and current guidelines.

How Regorafenib Works in Chemotherapy

Regorafenib is an oral targeted anticancer medicine from the class of multikinase inhibitors.
Although often grouped with modern systemic chemotherapy, Regonat regorafenib does not act like classic cytotoxic drugs that directly damage DNA.
Instead, it blocks multiple protein kinases that regulate tumour cell proliferation and tumour blood vessel formation.

Regonat 40 mg regorafenib tablets inhibit kinases including RAF family members and receptors in the VEGFR and PDGFR pathways.
These kinases drive tumour growth and angiogenesis in many colorectal cancers, GIST and hepatocellular carcinomas. By targeting these pathways,
Regonat 40 mg exerts both antiproliferative and anti-angiogenic effects, helping to slow tumour growth and reduce tumour blood supply.

Because these pathways also exist in healthy tissues, regorafenib therapy can cause systemic side effects, making regular monitoring by an experienced oncologist essential throughout treatment.

Dosage & Administration

The dosing schedule for Regonat 40 mg regorafenib tablets must always follow your oncology team’s instructions.
Many regorafenib protocols use a 28-day cycle with treatment given for three weeks followed by a one-week break, but exact doses and cycle numbers vary.

• Take Regonat tablets exactly as prescribed, at the same time each treatment day.
• Swallow Regonat 40 mg tablets whole with water; do not crush, split or chew them unless your pharmacist advises otherwise.
• Your doctor may recommend taking regorafenib 40 mg after a low-fat meal to support consistent absorption.
• Do not change the number of tablets, alter cycle patterns or stop Regonat on your own.
• If you miss a dose, follow written instructions from your treatment centre; do not double the next dose unless your doctor specifically instructs you to.

Regular blood tests, blood pressure checks and clinical visits are required so your oncology team can assess response and adjust Regonat 40 mg therapy if needed.

Precautions

Before starting Regonat 40 mg, tell your doctors about your full medical history and all medicines, supplements and herbal products you use. Important precautions include:

• Pre-existing liver disease, cirrhosis, viral hepatitis or abnormal liver function tests
• History of hypertension, coronary artery disease, heart failure or arterial clotting events
• Recent major surgery or planned operations, due to potential effects on wound healing
• Previous bleeding disorders, gastrointestinal ulcers, perforation or varices
• Use of anticoagulants or antiplatelet medicines that may increase bleeding risk
• Use of strong inducers or inhibitors of drug-metabolising enzymes that may alter regorafenib levels
• Pregnancy or breastfeeding; regorafenib tablets are not recommended and may harm an unborn baby

Men and women of child-bearing potential are usually advised to use effective contraception during and for a period after Regonat regorafenib treatment, as directed by their oncologist.

Regorafenib Side Effects

Common side effects

Common side effects of Regonat 40 mg regorafenib tablets include:

• Hand–foot skin reaction (redness, pain, thickening on palms and soles)
• Rash, dry skin or itching
• Fatigue, asthenia or low energy
• Diarrhea or loose stools
• Nausea, occasional vomiting or reduced appetite
• Abdominal discomfort or pain
• Hoarseness or voice changes
• Mild to moderate increases in blood pressure

These effects are often manageable with supportive care, blood pressure control, dermatologic treatment and dose modifications, as decided by your oncology team.

Serious side effects

Serious side effects of regorafenib require urgent medical attention and may include:

• Severe or uncontrolled hypertension, chest pain or shortness of breath
• Significant bleeding, such as black or bloody stools, vomiting blood or coughing up blood
• Signs of severe liver injury: yellowing of the skin or eyes, dark urine, pale stools, intense upper abdominal pain
• Severe, persistent abdominal pain that may indicate gastrointestinal perforation
• Severe hand–foot skin reaction with blistering or extensive peeling
• Sudden severe headache, vision changes or neurological symptoms suggestive of a vascular event

If you experience any of these symptoms while taking Regonat 40 mg, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Regonat 40 mg regorafenib tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and carton to protect them from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use after the expiry date printed on the packaging.

Ask your pharmacist or oncology centre how to safely dispose of unused or expired Regonat regorafenib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to providing safe access to key oncology medicines such as
Regonat 40 mg regorafenib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a reliable export record.

When you buy Regonat 40 mg online from Generic Meds Mart, you benefit from:

• Discreet, plain outer packaging for international delivery
• Clear, structured information about regorafenib 40 mg tablets to support discussions with your oncology team
• Tracked shipping options to many destinations
• Customer support for questions about ordering, payment and delivery

Order Now

Regonat 40 mg regorafenib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Regonat online, ensure your oncologist has confirmed regorafenib as part of your treatment plan and specified the total daily dose and number of packs required.

Select Regonat 40 mg (1 pack / 28 tablets), choose the quantity that matches your written plan, add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.